ID: ALA2115458

Max Phase: Preclinical

Molecular Formula: C28H42N6O6S2

Molecular Weight: 622.81

Molecule Type: Protein

Associated Items:

Representations

Canonical SMILES:  CSCC[C@H](NC(=O)[C@@H]1Cc2ccccc2CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](S)NC(=O)[C@@H](N)CCCCN)C(=O)O

Standard InChI:  InChI=1S/C28H42N6O6S2/c1-42-14-11-20(28(39)40)31-24(36)22-15-17-7-2-3-8-18(17)16-34(22)26(37)21-10-6-13-33(21)27(38)25(41)32-23(35)19(30)9-4-5-12-29/h2-3,7-8,19-22,25,41H,4-6,9-16,29-30H2,1H3,(H,31,36)(H,32,35)(H,39,40)/t19-,20-,21-,22-,25-/m0/s1

Standard InChI Key:  NLYDHALMGUSTFD-XHVFSLISSA-N

Associated Targets(non-human)

Protein farnesyltransferase 459 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: ProteinTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 622.81Molecular Weight (Monoisotopic): 622.2607AlogP: 0.08#Rotatable Bonds: 14
Polar Surface Area: 188.16Molecular Species: ZWITTERIONHBA: 9HBD: 6
#RO5 Violations: 2HBA (Lipinski): 12HBD (Lipinski): 7#RO5 Violations (Lipinski): 3
CX Acidic pKa: 3.73CX Basic pKa: 10.20CX LogP: -2.83CX LogD: -3.20
Aromatic Rings: 1Heavy Atoms: 42QED Weighted: 0.09Np Likeness Score: -0.35

References

1. Clerc F, Guitton J, Fromage N, Lelievre Y, Duchesne M, Tocque B, James-Surcouf E, Commercon A, Becquart J.  (1995)  Constrained analogs of KCVFM with improved inhibitory properties against farnesyl transferase,  (16): [10.1016/0960-894X(95)00314-J]

Source